Price | Pharma Marketer

Sanofi-Aventis readies $18.7B bid for Genzyme

Thursday, July 29th, 2010

Genzyme (GENZ) is in play.

Posted in: Pharma News | 0 Comments »

Read the full story

Bristol Ignores California Official Over AIDS Drug Price

Wednesday, July 28th, 2010

Over the past few weeks, Bristol-Myers Squibb was implored to lower the price of its Reyataz AIDS drug, given the funding crisis facing a growing number of state ADAP programs, which provide AIDS and HIV drugs to the public ( see here ). Among those lobbying the drugmaker is the AIDS Healthcare Foundation, which this week banned Bristol reps from its 11,000 or so clinics ( back story ). At least one California official, it turns out, has also beseeched Bristol, but has so far been ignored

Posted in: Regulatory | 0 Comments »

Read the full story

Bristol Ignores California Over AIDS Drug Price Flap

Wednesday, July 28th, 2010

Over the past few weeks, Bristol-Myers Squibb was implored to lower the price of its Reyataz AIDS drug, given the funding crisis facing a growing number of state ADAP programs, which provide AIDS and HIV drugs to the public ( see here ). Among those lobbying the drugmaker is the AIDS Healthcare Foundation, which this week banned Bristol reps from its 11,000 or so clinics ( back story )

Posted in: Regulatory | 0 Comments »

Read the full story

How much is Genzyme worth?

Tuesday, July 27th, 2010

The latest Genzyme sale saga goes on, though the most recent twist is getting hard to follow.

Posted in: Pharma News | 0 Comments »

Read the full story

AIDS Group Bans Bristol Sales Reps Over Pricing

Tuesday, July 27th, 2010

The AIDS Healthcare Foundation , which runs free AIDS clinics in various countries, including more than a dozen in the US, took the step over what it calls “unacceptable” pricing of the drugmaker’s Reyetaz AIDS medication. The move comes in response to the funding crisis at many state ADAP programs that provide AIDS and HIV drugs to the public ( see here )

Posted in: Regulatory | 0 Comments »

Read the full story

Sanofi Will Be Concerned About Overpaying for Genzyme

Tuesday, July 27th, 2010

EP Vantage submits: The initially hazy Sanofi-Aventis rumors are gradually turning into something more concrete.

Posted in: Pharma News | 0 Comments »

Read the full story

Elan CEO Is Inept, Misleading & Should Go: Investor

Thursday, July 22nd, 2010

Kelly Martin is always pissing one big investor or another.

Posted in: Regulatory | 0 Comments »

Read the full story

Making the Case for Merck

Saturday, July 10th, 2010

Bret Jensen submits: Overview : Merck & Co. (MRK) is a leading global drugmaker, producing a wide range of prescription drugs in many therapeutic classes in the U.S.

Posted in: Pharma News | 0 Comments »

Read the full story

Oil Tops $76, Capping Strong Week

Friday, July 9th, 2010

The price of crude passes the $76 mark on Friday, ending the week with the biggest gain in the price of crude oil since May.

Posted in: headlines | 0 Comments »

Read the full story

Does Eli Lilly Make for an Intelligent Investment or Intelligent Speculation Today?

Tuesday, June 29th, 2010

Bud Labitan submits Eli Lilly ( LLY ) discovers, develops, manufactures, and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 17 other countries

Posted in: Pharma News | 0 Comments »

Read the full story